Scleroderma NewsStem Cell Transplant Results Better than Standard Therapy in Severe Scleroderma Patients, Phase 2 Trial ShowsScleroderma NewsResults from a Phase 2 clinical trial shows that stem cell transplants can provide better long-term benefits th… Continue reading
Ask Reporter 24Global Synthetic Biology Workstation Market 2018-2022 – Increasing …Business Wire (press release)One trend in the market is growing number of startups in synthetic biology. With the increasing number of venture capitalists willing to f… Continue reading
FierceBiotech |
Gilead/Kite team up with Pfizer for CAR–T-mAb combination
FierceBiotech Yescarta (axicabtagene ciloleucel), approved by the FDA last year in the first wave of new CAR–T cell therapies, will be teamed up with Pfizer’s experimental humanized 4-1BB agonist utomilumab in patients with refractory large B-cell lymphoma. The … Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel …Business Wire (press release) |